Pharma Companies Resist Behavioral Health

With 61.5 million American adults suffering from a mental health disorder, the need for new psychiatric treatments is high. But in the past several years, the investment in psychiatric drugs has been decreasing.

In this article in PharmaVOICE, BDO’s Dr. Bill Bithoney shares insight into the challenges slowing down psychiatric drug research and behavioral health treatment.

Read the full article on the PharmaVOICE website: